Fluoxetine

Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) . Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa . Acute treatment of Panic Disorder, with or without agoraphobia . Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder.

12.1 Mechanism of Action Although the exact mechanism of fluoxetine is unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.

Following administration (40 mg/1 Capsule), Fluoxetine achieves Oral fraction absorbed ranges from 65% to 77% (Fluoxetine 40) bioavailability and oral tmax achieved within 2 to 4 hours following fluoxetine ingestion onset, governed by a Mean elimination half-life of 7 to 15 hours across adult Fluoxetine dosing terminal half-life through biotransformed through cyp2d6 pathways with mixed urinary/fecal clearance.

Before initiating Fluoxetine at 40 mg/1 Capsule, clinical safety checklists rule out when using fluoxetine capsules and olanzapine in combination, also refer to the contraindications section of the package insert for symbyax.; serotonin syndrome and maois: do not use maois intended to treat psychiatric disorders with fluoxetine capsules or within 5 weeks of stopping treatment with fluoxetine capsules.. Logged tolerability patterns center on nausea (8.4% of reports), headache (8.1% of reports), insomnia (6.4% of reports).